Archive for October 14th, 2011

INSM Phase 3 ARIKACE still on hold. CAPS reduces staff. OXGN terminates CEFF

Oct 14, 2011 No Comments by

Insmed Incorporated (Nasdaq CM: INSM) today announced that it has been notified by the FDA that it is continuing the clinical hold previously placed on its Phase 3 trial for ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease. As announced on August 1, 2011, the clinical holds placed on ARIKACE […]

Daily News Read more